Diabetic Nephropathy

Nephrology
6
Pipeline Programs
8
Companies
9
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 6 programs with unclassified modality

On Market (2)

Approved therapies currently available

U
NISOLDIPINEApproved
nisoldipine
Unknown Company
oral2023
U
SULARApproved
nisoldipine
Unknown Company
Dihydropyridine Calcium Channel Blocker [EPC]oral1995

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Fresenius Kabi
Fresenius KabiGermany - Bad Homburg
1 program
1
Ketosteril®Phase 41 trial
Active Trials
NCT00363987Completed179Est. Jun 2009
Bayer
BayerLEVERKUSEN, Germany
1 program
1
nisoldipinePhase 4Small Molecule1 trial
Active Trials
NCT00311870Completed52Est. Apr 1999
DS
Daiichi SankyoChina - Shanghai
1 program
1
CS-3150Phase 21 trial
Active Trials
NCT02345057Completed365Est. Jul 2016
Pfizer
PfizerNEW YORK, NY
1 program
1
PF-04634817Phase 23 trials
Active Trials
NCT01791855Completed32Est. Sep 2013
NCT01712061Completed226Est. Sep 2014
NCT01140672Completed48Est. Oct 2010
Astellas
AstellasChina - Shenyang
1 program
Beraprost sodiumN/A1 trial
Active Trials
NCT01796418Unknown102
Providence Therapeutics
1 program
CandesartanN/ASmall Molecule
M&
Merck & Co.RAHWAY, NJ
1 program
Dipeptidyl-Peptidase IV InhibitorsN/A1 trial
Active Trials
NCT02150707Completed17Est. Dec 2015
Sanofi
SanofiPARIS, France
1 program
Multifactorial InterventionN/A1 trial
Active Trials
NCT00708981Completed120Est. Dec 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Fresenius KabiKetosteril®
Bayernisoldipine
Daiichi SankyoCS-3150
PfizerPF-04634817
PfizerPF-04634817
PfizerPF-04634817
Merck & Co.Dipeptidyl-Peptidase IV Inhibitors
AstellasBeraprost sodium
SanofiMultifactorial Intervention

Clinical Trials (9)

Total enrollment: 1,141 patients across 9 trials

NCT00363987Fresenius KabiKetosteril®

Controlled Study to Evaluate Efficacy and Safety of α-KA Tab With Low Protein Diet (LPD) in Delaying the Progress of Type 2 Diabetic Nephropathy (DN)

Start: May 2006Est. completion: Jun 2009179 patients
Phase 4Completed
NCT00311870Bayernisoldipine

Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy

Start: Mar 1993Est. completion: Apr 199952 patients
Phase 4Completed
NCT02345057Daiichi SankyoCS-3150

A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria

Start: Jan 2015Est. completion: Jul 2016365 patients
Phase 2Completed
NCT01712061PfizerPF-04634817

A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy

Start: Dec 2012Est. completion: Sep 2014226 patients
Phase 2Completed
NCT01791855PfizerPF-04634817

PF-04634817 Renal Impairment Study

Start: May 2013Est. completion: Sep 201332 patients
Phase 1Completed
NCT01140672PfizerPF-04634817

A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects

Start: Jun 2010Est. completion: Oct 201048 patients
Phase 1Completed
NCT02150707Merck & Co.Dipeptidyl-Peptidase IV Inhibitors

The Differential Effects of Diabetes Therapy on Inflammation

Start: May 2014Est. completion: Dec 201517 patients
N/ACompleted
NCT01796418AstellasBeraprost sodium

Beraprost Sodium and Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy

Start: Mar 2013102 patients
N/AUnknown
NCT00708981SanofiMultifactorial Intervention

Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN)

Start: May 2007Est. completion: Dec 2013120 patients
N/ACompleted

Related Jobs in Nephrology

Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery

AstraZeneca
Sweden - Gothenburg
6d ago

Director, Strategy & Operations-Nephrology Franchise

Biogen
Cambridge, MA
1w ago
$195K - $269K/yr

Associate Director – Nephrology Market Access Strategy

Biogen
Cambridge, MA
1w ago
$164K - $226K/yr

Vice President, Head of Renal Sales

Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr

Medical Science Liaison, CardioRenal - Portland, OR

AstraZeneca
Portland - OR, US
1w ago

Area Sales Manager (Florida Region)

Outset Medical
Florida Region
1w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 companies competing in this space

Related Indications

Chronic Kidney Disease(86)Renal Impairment(67)End Stage Renal Disease(56)Kidney Transplantation(49)Renal Insufficiency(27)Chronic Kidney Diseases(25)Kidney Transplant(19)Diabetic Nephropathies(18)Kidney Diseases(17)Kidney Transplant Rejection(16)